Another treatment gap: restarting secondary prevention medications: the Women's Health Initiative.

ABSTRACT:

Background

Women's long-term patterns of evidence-based preventive medication utilization following a coronary heart disease (CHD) diagnosis have not been sufficiently studied.

Methods

Postmenopausal women 50-79 years were eligible for randomization in the Women's Health Initiative's (WHI) hormone trials if they met inclusion and exclusion criteria and were >80% adherent during a placebo-lead-in period and in the dietary modification trial if they were willing to follow a 20% fat diet. Those with adjudicated myocardial infarction or coronary revascularization after the baseline visit were included in the analysis (n=2627). Baseline visits occurred between 1993 and 1998, then annually until the trials ended in 2002 through 2005; medication inventories were obtained at baselin

SUBMITTER: Robinson JG 

PROVIDER: S-EPMC2845400 | biostudies-literature | 2010 Jan-Feb

REPOSITORIES: biostudies-literature